TRB Wealth Management LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,722 shares of the conglomerate’s stock, valued at approximately $518,000.
Several other hedge funds also recently bought and sold shares of the company. Sumitomo Life Insurance Co. purchased a new stake in Danaher in the 2nd quarter worth $1,255,000. Landscape Capital Management L.L.C. purchased a new position in shares of Danaher in the second quarter valued at about $545,000. Korea Investment CORP purchased a new position in shares of Danaher in the second quarter valued at about $79,057,000. EP Wealth Advisors LLC bought a new position in shares of Danaher in the second quarter worth about $3,807,000. Finally, Heartland Bank & Trust Co purchased a new stake in shares of Danaher during the second quarter worth about $385,000. Institutional investors own 79.05% of the company’s stock.
Danaher Trading Up 1.6%
Shares of DHR stock opened at $219.42 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $154.25 billion, a price-to-earnings ratio of 38.97, a price-to-earnings-growth ratio of 2.69 and a beta of 0.78. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The stock’s 50-day moving average price is $195.80 and its 200-day moving average price is $192.61.
Wall Street Analysts Forecast Growth
DHR has been the topic of several recent analyst reports. Piper Sandler initiated coverage on Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Guggenheim cut their price objective on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. HSBC cut their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Citigroup assumed coverage on shares of Danaher in a report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price on the stock. Finally, TD Cowen dropped their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $228.91.
View Our Latest Analysis on DHR
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
